Dahir, K. M. http://orcid.org/0000-0002-9980-9138
Rush, E. T. http://orcid.org/0000-0002-8147-7315
Diaz-Mendoza, S.
Kishnani, P. S.
Funding for this research was provided by:
Alexion Pharmaceuticals
Article History
Received: 18 September 2023
Accepted: 21 November 2023
First Online: 18 January 2024
Declarations
:
: KMD is a clinical trial investigator for, has received honoraria from, and serves on an Alexion Hypophosphatasia Registry Board for Alexion Pharmaceuticals Inc. ETR has received grants or contracts, consulting fees, honoraria, and support for attending meetings and/or travel from AstraZeneca/Alexion; he also serves on the Alexion Registry Board. SDM was previously employed as a consultant at OPEN Health. PSK has received grant funding and honoraria from AstraZeneca/Alexion and serves as Chair of the Alexion Hypophosphatasia Registry Board.
: Institutional ethics committee approval was not necessary because the participating healthcare professionals were recruited by virtue of their professional role.
: No human patients and/or animals participated in the study.
: Not applicable.